Novo Nordisk Blocks Eli Lilly Weight Loss Drug Ads in U.S. Federal Injunction
Novo Nordisk filed a motion for a preliminary injunction in the U.S. District Court for the District of New Jersey to halt Eli Lilly’s advertising campaigns for obesity and diabetes medications in the United States.
The pharmaceutical rival alleges the competing advertisements rely on misleading dose comparisons that portray the rival's GLP-1 drugs as superior. The court’s decision on the temporary marketing restraint will be determined as the broader lawsuit proceeds.
From the sources (4 posts)
@wallstengineNovo Nordisk $NVO asked a federal court to temporarily halt Eli Lilly’s $LLY GLP-1 advertising campaigns while its lawsuit proceeds, alleges the ads use misleading dose comparisons to portray Lilly’s drugs as superior.
@firstsquawkNOVO NORDISK: FILED A MOTION FOR A PRELIMINARY INJUNCTION IN THE US DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY
@cnbcNovo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads
@stockmktnewzNovo Nordisk $NVO said today it has filed a preliminary injunction to immediately block Eli Lilly $LLY from running obesity and diabetes drug advertisements in the United States 🇺🇸 - SeekingAlpha